Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04258826 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate LY3154207 on the Brain of Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04258826 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 16 participants.
The verdict
NCT04258826, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how LY3154207 affects the brain of healthy participants by using magnetic resonance imaging. The study will last up to about nine weeks for each participant and may include up to four visits to the study center.
Interventions
- DRUG Placebo
- DRUG LY3154207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2022-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04258826
The ClinicalTrials.gov registry entry for NCT04258826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04258826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04258826 about?
NCT04258826 is a clinical study titled "A Study to Evaluate LY3154207 on the Brain of Healthy Participants". The purpose of this study is to learn more about how LY3154207 affects the brain of healthy participants by using magnetic resonance imaging. The study will last up to about nine weeks for each participant and may include up to four visits to the study center.
What is the current status of trial NCT04258826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-01-15. Estimated completion is 2022-01-28.
What interventions are being tested in trial NCT04258826?
The interventions under investigation include: Placebo (DRUG), LY3154207 (DRUG).
Who is sponsoring clinical trial NCT04258826?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.